Skip to content

D-serine and Cognitive Remediation in Schizophrenia

D-serine and Cognitive Remediation in Schizophrenia: Open Label Pilot

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02156908
Enrollment
8
Registered
2014-06-05
Start date
2014-08-31
Completion date
2015-12-31
Last updated
2020-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

cognitive remediation

Brief summary

The investigators will test the effects of 3 days of D-serine (DSR) on auditory plasticity in a sensory based remediation (SBR) paradigm

Detailed description

We will enroll 8 subjects in an open label, three session pilot in patients will receive three sessions of tone matching SBR. 5 Subjects will receive D-serine (60mg/kg) taken 1x each week during the SBR sessions. Subjects will receive study drug 30 minutes prior to session. 3 subjects received no intervention

Interventions

DRUGD-serine

D-serine 60 mg/kg

Sponsors

Nathan Kline Institute for Psychiatric Research
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* 18 to 64 years old, * IQ≥85 and * estimated Glomerular Filtration Rate (GFR) ≥60. All oral and depot antipsychotics (with the exception of clozapine) are allowable. Patients must be on their antipsychotic medication for 1 month and stable on dose of antipsychotic and adjunctive medications for 2 weeks prior to study entry.

Exclusion criteria

* history of neurological visual or hearing impairment, * active suicidal ideation on the Columbia Suicide Severity Rating Scale (C-SSRS), * current alcohol or drug abuse (\<1 month) or substance dependence (\<4 months). All women of child-bearing potential must have a negative urine pregnancy test at the baseline visit. We require an IQ of ≥85 to ensure that subjects will have a capacity to learn. In our cross-sectional studies, we have observed an IQ≥85 in over 90% of candidates, suggesting that this is not an overly restrictive criterion.

Design outcomes

Primary

MeasureTime frameDescription
Mismatch Negativity (MMN)3 weeksAn MMN event is evoked by a discernible change in the pitch of a repetitive auditory stimulation. The stronger the response to a difference (i.e., the more negative the amplitude of the MMN), the better the outcome. MMN was obtained to pitch deviant stimuli pre-post auditory plasticity training, utilizing deviants to the same base frequencies as the auditory plasticity sessions, (i.e. 500, 1000, and 2000 Hz), with \ 10 minutes of each base frequency. MMN will be conducted at baseline and after the final session. Reported outcome is change in MMN between baseline and final within session.

Secondary

MeasureTime frameDescription
Tone Matching Thresholdthree weeksChange tone matching threshold (the percent difference in pitch of two consecutively played tones that can be distinguished), higher numbers represent better outcomes. D-serine outcomes are for 2 consecutive D-serine sessions

Countries

United States

Participant flow

Pre-assignment details

Please see NCT01474395 for a related parallel study involving 13 schizophrenia patients and 13 healthy controls. Participants in NCT01474395 were not enrolled in the current study, i.e., both studies included separate groups of participants

Participants by arm

ArmCount
D-serine
D-serine D-serine: D-serine 60 mg/kg
5
No Intervention3
Total8

Baseline characteristics

CharacteristicD-serineNo InterventionTotal
Age, Continuous43.2 years
STANDARD_DEVIATION 9.4
45.4 years
STANDARD_DEVIATION 14.3
44.0 years
STANDARD_DEVIATION 10.5
Sex: Female, Male
Female
1 Participants0 Participants1 Participants
Sex: Female, Male
Male
4 Participants3 Participants7 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 50 / 3
other
Total, other adverse events
0 / 50 / 3
serious
Total, serious adverse events
0 / 50 / 3

Outcome results

Primary

Mismatch Negativity (MMN)

An MMN event is evoked by a discernible change in the pitch of a repetitive auditory stimulation. The stronger the response to a difference (i.e., the more negative the amplitude of the MMN), the better the outcome. MMN was obtained to pitch deviant stimuli pre-post auditory plasticity training, utilizing deviants to the same base frequencies as the auditory plasticity sessions, (i.e. 500, 1000, and 2000 Hz), with \ 10 minutes of each base frequency. MMN will be conducted at baseline and after the final session. Reported outcome is change in MMN between baseline and final within session.

Time frame: 3 weeks

ArmMeasureValue (MEAN)Dispersion
D-serineMismatch Negativity (MMN).086 micro voltsStandard Deviation 0.36
no InterventionMismatch Negativity (MMN)0.31 micro voltsStandard Deviation 0.29
Secondary

Tone Matching Threshold

Change tone matching threshold (the percent difference in pitch of two consecutively played tones that can be distinguished), higher numbers represent better outcomes. D-serine outcomes are for 2 consecutive D-serine sessions

Time frame: three weeks

ArmMeasureValue (MEAN)Dispersion
D-serineTone Matching Threshold11 percentage of difference in pitchStandard Deviation 3.6
no InterventionTone Matching Threshold2.3 percentage of difference in pitchStandard Deviation 0.7

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026